Healthcare Business - Page 2

Why Big Pharma Is Not at Fault for Record Drug Spending

With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it as the industry punching bag. But the truth is, Big ...
Read Full Story »

Merck’s Accelerated Keytruda Lung Cancer Approval Creates 3 Moves

It is no secret that pharma and biotech shares have had to deal with at least some headwinds over the past year. It turns out that drug pricing concerns and ...
Read Full Story »

Why Sangamo Therapeutics Is Surging

Sangamo Therapeutics Inc. (NASDAQ: SGMO) saw its shares skyrocket early on Thursday after a critical business update. Although the company did recently report its first-quarter results, this is not what’s ...
Read Full Story »

Major Biotech Short Interest Remains Mixed

The short interest data are out for the most recent settlement date, April 28. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Short Interest in Major Pharma Shrinks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

4 Biotech and Specialty Pharma Stocks With 80% to 200% Upside Potential

Needless to say, the biotech world has had a very difficult 18 months. Even the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, have suffered ...
Read Full Story »

Is Valeant for Real This Time?

When Valeant Pharmaceuticals International Inc. (NYSE: VRX) released its first-quarter financial results before the markets opened on Tuesday, it totally shocked investors. This stock has trended lower for a long ...
Read Full Story »

How Valeant Earnings Beat Estimates

Valeant Pharmaceuticals International Inc. (NYSE: VRX) reported first-quarter 2017 results before markets opened Tuesday. The company reported quarterly diluted earnings per share (EPS) of $1.79 and revenues of $2.11 billion. ...
Read Full Story »

MannKind Jumps After Amazon Prime Takes on One Drop

MannKind Corp. (NASDAQ: MNKD) saw its shares make a massive gain on Monday after it was announced that its One Drop|Chrome is now available on Amazon Prime. Overall this is ...
Read Full Story »

Horizon Pharma Sinks on Missed Earnings and Guidance

Horizon Pharma PLC (NASDAQ: HZNP) saw its shares hit a 52-week low on Monday after the company released its first-quarter financial results. The company said that it had $0.21 in ...
Read Full Story »

Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated?

Shares of Immunomedics Inc. (NASDAQ: IMMU) saw a massive gain on Friday after the company announced the termination of its licensing deal with Seattle Genetics Inc. (NASDAQ: SGEN). It may seem ...
Read Full Story »

AmpliPhi Biosciences Crumbles After Announcing Secondary Offering

AmpliPhi Biosciences Corp. (NYSEMKT: APHB) saw its shares crater on Friday after the company announced that pricing of its secondary offering. The company will be offering roughly 6.96 million shares ...
Read Full Story »

JPMorgan Has 3 Top Pick Large Cap Pharmaceuticals to Buy for the Rest of 2017

One segment in the markets that has been dogged with issues for almost two years is the big pharmaceuticals, as numerous factors have kept the lid on share prices and, ...
Read Full Story »

Pieris Pharma Soars on AstraZeneca Collaboration

Shares of Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) saw perhaps one of the biggest gains on Wednesday after the company announced a critical collaboration with AstraZeneca PLC (NYSE: AZN). Specifically, the two ...
Read Full Story »

Gilead Faces Serious Conundrum: Value Trap vs Real Value

Gilead Sciences Inc. (NASDAQ: GILD) had perhaps become the greatest biotech growth story of all time. In a world that only rewards what you will do next rather than what ...
Read Full Story »